Neurogene Inc. (NASDAQ:NGNE - Get Free Report) shares were up 3.3% during trading on Friday . The stock traded as high as $39.59 and last traded at $39.59. Approximately 10,490 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 130,354 shares. The stock had previously closed at $38.33.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on NGNE shares. Stifel Nicolaus started coverage on Neurogene in a report on Friday, January 5th. They issued a "buy" rating and a $31.00 target price on the stock. HC Wainwright boosted their target price on Neurogene from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, March 19th. TD Cowen started coverage on Neurogene in a report on Thursday, January 4th. They issued an "outperform" rating on the stock. Finally, William Blair started coverage on Neurogene in a report on Thursday, March 21st. They issued an "outperform" rating and a $61.00 target price on the stock.
Get Our Latest Stock Report on Neurogene
Neurogene Trading Up 3.6 %
The stock has a 50-day moving average of $37.33. The company has a market cap of $510.15 million, a PE ratio of -3.21 and a beta of 1.26.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC bought a new position in Neurogene in the 4th quarter worth approximately $1,401,000. Vanguard Group Inc. bought a new stake in shares of Neurogene during the 4th quarter valued at $977,000. ADAR1 Capital Management LLC bought a new stake in shares of Neurogene during the 4th quarter valued at $105,000. US Bancorp DE bought a new stake in shares of Neurogene during the 4th quarter valued at $67,000. Finally, Great Point Partners LLC bought a new stake in shares of Neurogene during the 4th quarter valued at $19,268,000. Institutional investors own 52.37% of the company's stock.
Neurogene Company Profile
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
See Also
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
